📖 Core Concepts
Core Concepts — Immunology: Molecules, Cells, and the Immune Response
1. What immunology is really about: recognition, context, and controlled action
Skipper, the central problem of immunology is not simply “How does the body kill microbes?” It is how a living system decides when molecular differences justify a potentially destructive response. An immune system must detect infection, contain damaged cells, preserve useful resident microbes, tolerate food and self tissues, and remember previous threats. These tasks sometimes conflict. A response strong enough to eliminate a pathogen may damage the tissue it is supposed to protect; a response restrained enough to avoid autoimmunity may permit infection or cancer.
This makes immunology a science of recognition coupled to decision-making. Binding an antigen is one event. Deciding whether to attack, tolerate, contain, or remember it requires additional information: the cell doing the recognizing, its developmental history, the surrounding cytokines, the anatomical location, and the presence or absence of costimulatory signals. “Foreignness” alone is not a complete explanation of immune activation. [Abbas, Lichtman & Pillai, 2021; Murphy, Weaver & Berg, 2022]
Journal principle: Recognition supplies specificity; context determines the meaning of recognition.
The subject brings together nearly everything you have already studied. Cell biology explains trafficking, secretion, phagocytosis, and cell–cell contact. Molecular biology explains receptor gene rearrangement and inducible gene expression. Organic chemistry explains the functional groups that make molecular recognition possible. Thermodynamics explains binding, while biochemistry explains how binding becomes a signal or an enzymatic reaction. Immunology adds a further level: these molecular events are distributed across interacting populations of cells.
2. The immune system is an organized network, not a collection of independent weapons
The first useful distinction is between innate and adaptive immunity. Innate recognition relies mainly on receptors encoded in the inherited genome. Adaptive recognition relies on highly diverse antigen receptors assembled during lymphocyte development. Innate responses are usually available rapidly; a primary adaptive response typically requires time for rare antigen-specific lymphocytes to activate, proliferate, and differentiate. Yet the two systems are not separate defensive lines that work independently. Innate cells initiate and shape adaptive responses, while antibodies and T cells redirect and strengthen innate effector mechanisms. [Murphy, Weaver & Berg, 2022]
- Neutrophils are rapidly recruited phagocytes that ingest microbes and deploy antimicrobial granule contents and reactive oxygen species. Their effectiveness comes with a risk of collateral tissue damage.
- Macrophages combine phagocytosis, cytokine production, removal of dead cells, and tissue repair. Many tissue-resident macrophage populations are established early in development and maintained locally; not every macrophage is simply a recently differentiated blood monocyte.
- Dendritic cells, or DCs, are particularly important for activating naive T cells. They connect events in peripheral tissues with decisions in lymphoid organs.
- Natural killer, or NK, cells integrate activating and inhibitory signals to detect stressed or infected cells. Reduced expression of normal MHC class I can remove inhibitory input—a principle called missing-self recognition—but the balance of signals, not missing MHC alone, determines the outcome.
- Mast cells are tissue-resident cells that release mediators involved in vascular responses, parasite defense, and immediate allergic reactions.
- B cells recognize native antigen through the B-cell receptor, present processed antigen to helper T cells, and can differentiate into antibody-secreting plasma cells or memory B cells.
- T cells include CD4 helper and regulatory populations and CD8 cytotoxic populations. Conventional T cells recognize antigen as peptide bound to MHC, rather than as freely dissolved intact protein.
Anatomy makes this network efficient. The bone marrow and thymus are primary lymphoid organs, where B- and T-cell development occurs, respectively. Lymph nodes, the spleen, and mucosal lymphoid tissues are major sites where mature lymphocytes encounter antigen and initiate responses. Lymph nodes sample material arriving from tissues through lymph; the spleen samples blood-borne material.
Think of a lymph node as a carefully routed meeting place. A naive T cell specific for a particular microbial peptide is rare. By bringing antigen-bearing DCs and recirculating lymphocytes into the same structured space, the node turns an improbable random encounter into a repeatable biological process. Chemokines and adhesion molecules provide the routing instructions. [Abbas, Lichtman & Pillai, 2021]
3. Innate immunity recognizes patterns in the right—or wrong—places
Innate pattern recognition receptors, or PRRs, recognize conserved microbial features and signals associated with cellular damage. Microbial ligands are often called pathogen-associated molecular patterns, although many also occur in nonpathogenic microbes. Damage-associated molecular patterns arise when molecules are released or exposed in abnormal contexts.
The location of a molecule matters as much as its identity. Nucleic acid in an endosome or the cytosol may indicate infection, whereas nucleic acid safely contained in its usual cellular compartment does not necessarily trigger the same response. Compartmentalization is therefore part of immune discrimination, not just a background detail from cell biology. [Murphy, Weaver & Berg, 2022]
- Toll-like receptors, or TLRs, occur at the cell surface and in endosomes. Different family members detect microbial lipids, proteins, or nucleic acids.
- NOD-like receptors, or NLRs, are intracellular sensors and signaling proteins. Some detect bacterial products; some participate in inflammasome assembly.
- C-type lectin receptors, or CLRs, include receptors that recognize carbohydrate patterns, particularly on fungi, and can promote uptake and inflammatory signaling.
- RIG-I-like receptors detect features of cytosolic viral RNA and help induce antiviral type I interferon responses.
PRRs commonly activate transcription factors such as NF-κB and interferon regulatory factors. The resulting response can include inflammatory cytokines, chemokines, antiviral proteins, and increased costimulatory molecule expression. This is an important molecular bridge: detecting a microbial pattern changes how an antigen-presenting cell will later instruct a T cell.
Inflammasomes illustrate how recognition can be coupled directly to proteolysis. These cytosolic complexes activate inflammatory caspases; in canonical inflammasome pathways, caspase-1 processes pro-IL-1β and pro-IL-18 into active cytokines and cleaves gasdermin D. Gasdermin D fragments form membrane pores that support cytokine release and can produce an inflammatory form of cell death called pyroptosis.
Common canonical inflammasome sequence:
Priming → increased expression of inflammatory components
Activation signal → sensor assembly + adaptor recruitment + procaspase-1
→ active caspase-1
→ pro-IL-1β / pro-IL-18 cleavage
→ gasdermin D cleavage → membrane pores → possible pyroptosis
The familiar two-step “priming plus activation” model is especially useful for understanding NLRP3, but it should not be imposed identically on every inflammasome pathway. Likewise, NLRP3 should not be pictured as a receptor that directly binds every chemically diverse substance associated with its activation; many such stimuli converge on disturbances in cellular physiology. [Abbas, Lichtman & Pillai, 2021; Murphy, Weaver & Berg, 2022]
Cytokines are context-dependent instructions. The same cytokine can affect several cell types, and different cytokines can produce overlapping effects. These properties are called pleiotropy and redundancy. Receptor expression, signal strength, timing, and combinations with other signals determine the outcome. A cytokine is less like a sentence with a fixed meaning and more like a word whose meaning depends on the surrounding conversation.
4. Complement converts recognition into an amplified biochemical cascade
The complement system is a network of soluble and membrane-associated proteins that promotes microbial clearance. It is a useful extension of your biochemistry training: regulated proteolysis creates enzyme complexes, which generate more active products, producing amplification at a surface.
- The classical pathway often begins when C1q recognizes clustered Fc regions of antigen-bound IgM or suitable IgG subclasses. It can also be initiated through certain non-antibody ligands.
- The lectin pathway begins when recognition proteins such as mannose-binding lectin or ficolins bind suitable surface patterns.
- The alternative pathway involves low-level spontaneous C3 activation and strongly amplifies C3b deposition on surfaces that fail to regulate it effectively. It also amplifies activation initiated by the other pathways.
Classical / lectin pathway → C3 convertase: C4b2a Alternative pathway → C3 convertase: C3bBb C3 → C3a + C3b C3a: inflammatory signaling C3b: surface tagging and support for further complement activation C5 convertase formation → C5 → C5a + C5b C5a: potent inflammatory and leukocyte-recruiting activities C5b + C6 + C7 + C8 + C9 → membrane attack complex, C5b–9
Opsonization means coating a target with molecules that make it easier for phagocytes to recognize and ingest it. C3b and its derivative iC3b are important opsonins. The membrane attack complex can damage susceptible membranes, but complement does much more than lyse cells; opsonization and inflammatory recruitment are often its more important functions.
A beautiful chemical detail is that C3 activation exposes a reactive thioester in C3b, enabling covalent attachment to nearby surfaces. Thus, a transient activation event can create a persistent molecular tag. Host regulators—including factor H, factor I, CD46, CD55, and CD59—limit different stages of the cascade. The distinction between protected self and vulnerable target depends substantially on this regulation, not on a magical ability of complement enzymes to identify every foreign object. [Murphy, Weaver & Berg, 2022]
5. MHC molecules display a processed sample of cellular life
Conventional T cells do not directly inspect all intact proteins inside another cell. Instead, they examine peptides displayed by major histocompatibility complex molecules. In humans, these molecules are called human leukocyte antigens, or HLA molecules. Antigen presentation is therefore a sampling and display system: proteins are processed, selected peptides bind MHC, and peptide–MHC complexes reach the cell surface.
This differs fundamentally from antibody recognition. An antibody can bind an exposed three-dimensional surface on an intact protein. A conventional αβ T-cell receptor recognizes a composite surface made by both a peptide and an MHC molecule. Consequently, antibody epitopes and T-cell epitopes are not interchangeable concepts. [Abbas, Lichtman & Pillai, 2021]
MHC class I consists of a polymorphic heavy chain associated with β2-microglobulin. Its peptide-binding groove is closed at the ends and generally accommodates peptides about 8–10 amino acids long, although longer peptides can bind by bulging or adopting other conformations. Class I is expressed by almost all nucleated cells and presents peptides to CD8 T cells.
Typical MHC class I pathway: Cytosolic protein → proteasomal degradation → peptide transport into ER by TAP → peptide trimming and loading onto MHC I → peptide–MHC I travels through Golgi to cell surface → recognition by a CD8 T cell
MHC class II consists of α and β chains. Its groove is open at the ends, allowing peptides to extend beyond a roughly nine-residue binding core. Presented peptides are commonly around 13–25 residues long, with substantial variation. Class II is expressed mainly by professional antigen-presenting cells, including DCs, B cells, and macrophages, and presents peptides to CD4 T cells.
Typical MHC class II pathway: Extracellular protein → endocytosis → endosomal / lysosomal proteolysis MHC II assembled in ER + invariant chain → trafficking to endosomal compartments → invariant-chain degradation leaves CLIP in the groove → HLA-DM promotes CLIP release and peptide exchange → peptide–MHC II reaches cell surface → recognition by a CD4 T cell
These are dominant routes, not absolute laws. Cross-presentation allows certain DCs to display peptides from extracellular material on MHC class I, enabling CD8 T-cell priming when the DC itself is not infected. Intracellular material can also enter class II pathways, including through autophagy-related routes.
HLA genes are highly polymorphic, meaning that many alleles exist in the population, and they are expressed codominantly. Differences in binding-groove chemistry change which peptide side chains fit preferred pockets. One HLA molecule can bind many peptide sequences, but not all sequences bind equally well.
HLA typing identifies the alleles a person carries. It matters for transplantation, disease associations, and interpretation of peptide presentation. It does not reveal exactly which peptides that person is presenting at a particular moment, nor does it by itself predict whether a specific immune response will occur. [Murphy, Weaver & Berg, 2022]
Journal principle: A protein does not contain a universally visible set of T-cell epitopes. Visibility depends on processing, HLA binding, display, and the available T-cell repertoire.
6. Adaptive receptor diversity is generated before the body knows what it will encounter
The adaptive immune system solves an extraordinary information problem: a finite genome must support recognition of an enormous range of molecular structures. The solution is not one inherited gene for each possible antigen. Instead, developing lymphocytes assemble receptor genes from reusable segments and introduce additional variation at the joining sites.
In V(D)J recombination, RAG1 and RAG2 initiate recombination at recombination signal sequences. Joining is constrained by the 12/23 rule, and DNA repair machinery completes the rearrangement. Immunoglobulin heavy chains and TCR β chains use V, D, and J segments; immunoglobulin light chains and TCR α chains use V and J segments.
Sources of receptor diversity: Segment choice × junctional diversity × pairing of independently rearranged chains Junctional diversity includes: imprecise joining nucleotide deletion hairpin-processing-associated P nucleotides TdT-mediated N-nucleotide addition
This is a mechanism diagram rather than an exact numerical formula: segment usage is unequal, some rearrangements are nonproductive, and developmental selection removes many cells. Diversity is especially concentrated in CDR3, a region that often makes major contributions to antigen recognition.
Allelic exclusion helps ensure that a B cell expresses one predominant antigen-receptor specificity rather than several competing ones. Related controls operate in T-cell development, though TCR α-chain allelic exclusion is less strict. “One lymphocyte, one specificity” is therefore an excellent organizing approximation, not an exceptionless molecular law.
The antigen then selects pre-existing clones whose receptors can bind it; it does not instruct their initial receptor sequence. Selected cells proliferate, creating a population descended from the original responsive cell. This is clonal selection. The distinction is central: receptor generation is anticipatory and partly stochastic, whereas expansion is antigen dependent. [Abbas, Lichtman & Pillai, 2021]
7. T-cell education makes recognition useful—and limits its danger
Random receptor generation inevitably produces useless and potentially harmful receptors. T-cell development therefore includes selection in the thymus. Immature cells pass through a stage expressing both CD4 and CD8, and their receptors are tested against self peptide–MHC complexes.
- Positive selection preserves cells capable of interacting productively with self MHC. Cells that cannot receive an adequate survival signal generally die by neglect.
- Negative selection removes many cells that respond too strongly to self peptide–MHC. Some self-reactive cells instead contribute to regulatory T-cell development under appropriate conditions.
- Lineage commitment usually associates MHC class I recognition with the CD8 lineage and class II recognition with the CD4 lineage.
The surprising point is that useful T cells must be somewhat self-reactive: they must recognize self MHC and receive appropriate self peptide–MHC signals. Tolerance does not mean eliminating every receptor that can interact with self. It means limiting interactions likely to produce destructive activation.
Medullary thymic epithelial cells express many tissue-associated proteins, with transcriptional regulators such as AIRE and FEZF2 contributing to this unusually broad self-antigen display. But thymic sampling is not complete. Peripheral tolerance remains essential through anergy, deletion, inhibitory signaling, and regulatory T-cell suppression. B cells also undergo tolerance mechanisms, including receptor editing, deletion, and anergy. [Murphy, Weaver & Berg, 2022]
8. T-cell activation is a biochemical coincidence detector
A mature naive T cell must not launch a response whenever it encounters a recognizable peptide. Activation integrates several classes of input:
- Signal 1: TCR recognition of peptide–MHC, supported by CD4 or CD8.
- Signal 2: costimulation, classically CD28 on the T cell binding B7 molecules—CD80 or CD86—on the antigen-presenting cell.
- Signal 3: cytokines that influence differentiation, survival, and the type of effector response.
This framework is particularly useful for naive T-cell priming. It is not a claim that every effector T cell has identical activation requirements. It explains, however, why DC maturation matters: microbial sensing can increase B7 expression and cytokine production, linking antigen recognition to evidence of infection or inflammation.
Simplified TCR signaling: TCR binds peptide–MHC → Lck phosphorylates ITAMs in CD3 and ζ signaling chains → ZAP-70 recruitment and activation → LAT / SLP-76 signaling assemblies → PLC-γ1 activation PLC-γ1 cleaves PIP2 → IP3 + DAG IP3 → Ca2+ signaling → calmodulin / calcineurin → NFAT activation DAG → PKC-θ-associated pathways → NF-κB activation DAG → Ras / MAP kinase pathways → AP-1 activation Coordinated transcription → IL-2, survival, proliferation, differentiation
From your molecular biology background, notice that the final decision is not located in one receptor. It emerges from a signaling network and cooperative gene regulation. NFAT activity without the usual accompanying activation program can contribute to tolerance-associated states rather than productive activation.
TCR discrimination also shows why equilibrium affinity alone is insufficient. Binding duration, force, receptor organization, coreceptor participation, and sequential signaling steps all matter. Kinetic proofreading models propose that productive signaling requires completion of successive steps while ligand engagement persists. Many short-lived interactions fail before reaching the activation threshold. [Murphy, Weaver & Berg, 2022]
Activated CD4 T cells acquire overlapping but useful functional programs:
- Th1: associated with T-bet and IFN-γ; promotes macrophage activation and defense against intracellular pathogens.
- Th2: associated with GATA3 and IL-4, IL-5, and IL-13; supports responses involving eosinophils, mast cells, mucus production, and helminth defense, while also contributing to allergy.
- Th17: associated with RORγt and IL-17-family cytokines; supports barrier defense and neutrophil recruitment against extracellular bacteria and fungi.
- T follicular helper, or Tfh, cells: associated with BCL6 and follicular localization; provide critical help to B cells, including through CD40L and cytokines such as IL-21.
- Regulatory T, or Treg, cells: commonly characterized by FOXP3; restrain responses through mechanisms including CTLA-4-dependent regulation and suppressive cytokines.
These are regulatory programs, not perfectly sealed boxes. Subsets can share features and exhibit plasticity. CD8 effector T cells, meanwhile, can kill targets using perforin and granzymes or death-receptor pathways such as Fas–Fas ligand, generally inducing programmed cell death rather than simply bursting the target. [Abbas, Lichtman & Pillai, 2021]
9. B-cell responses combine recognition, collaboration, and evolution
The B-cell receptor consists of membrane immunoglobulin associated with signaling proteins Igα and Igβ. Antigen engagement activates pathways involving kinases such as Lyn, Syk, and BTK. The BCR also internalizes bound antigen, allowing the B cell to display derived peptides on MHC class II.
For many protein antigens, durable, high-quality antibody responses depend on linked recognition. A B cell binds one exposed part of an antigen, internalizes it, and presents peptides to a helper T cell. The B-cell epitope and T-cell epitope need not be the same sequence; they must be linked through material that the B cell can capture and process.
Conjugate vaccines exploit this principle. A B cell recognizes a polysaccharide attached to a carrier protein, internalizes the conjugate, and presents carrier-derived peptides to helper T cells. The resulting antibody can still recognize the polysaccharide. The protein supplies access to T-cell help rather than becoming the only antibody target.
Some antigens can activate B cells with limited conventional T-cell help. These T-independent responses often involve repetitive antigen structures and additional innate signals. They tend to have less germinal-center maturation and more limited durable memory than classic T-dependent protein responses, although they should not be reduced to “IgM only, with absolutely no memory.” [Murphy, Weaver & Berg, 2022]
Within germinal centers, activated B cells proliferate, mutate antibody variable-region genes, and compete for antigen and Tfh help. The dark and light zones support different aspects of this iterative process. Selection favors cells that successfully capture and present antigen and obtain survival and differentiation signals.
Germinal-center cycle: Clonal proliferation → somatic hypermutation → altered BCR binding properties → competition for antigen and Tfh help → selective survival and further proliferation → plasma-cell and memory-cell differentiation
Activation-induced cytidine deaminase, or AID, initiates both somatic hypermutation and class switch recombination by converting cytosine to uracil in DNA. The outcome depends on where the lesions occur and how they are processed:
- Somatic hypermutation: error-prone processing introduces mutations into immunoglobulin variable-region genes. Mutation is not intrinsically beneficial; selection enriches useful variants.
- Class switch recombination: lesions in switch regions lead to DNA breaks and recombination that connect the existing VDJ region to a different heavy-chain constant-region gene.
Affinity maturation changes the quality of binding; class switching changes the available effector functions while preserving the rearranged antigen-binding variable region. These processes can occur during the same response, but they solve different problems. Coexpression of IgM and IgD by many naive B cells usually arises through alternative RNA processing, not conventional class switch recombination. TCR genes, unlike antibody genes, do not undergo somatic hypermutation during ordinary adaptive responses. [Abbas, Lichtman & Pillai, 2021]
10. Antibodies connect molecular recognition to modular effector functions
A conventional IgG antibody contains two heavy chains and two light chains held together by noncovalent interactions and disulfide bonds. Its immunoglobulin domains form stable structural modules. Each antigen-binding site combines a heavy-chain variable domain and a light-chain variable domain; six complementarity-determining regions, or CDRs, form much of the binding surface.
The Fab regions mediate antigen binding, while the Fc region engages effector systems such as Fc receptors and complement. This creates a powerful modular architecture: the adaptive immune system varies the recognition end while using a more limited set of output mechanisms.
Your thermodynamics background gives a quantitative language for binding:
For an idealized single binding site: Ab + Ag ⇌ Ab·Ag Kd = [Ab][Ag] / [Ab·Ag] Fractional occupancy: θ = [Ag]free / (Kd + [Ag]free) Standard binding free energy: ΔG°bind = RT ln(Kd / C°) C° = 1 mol L−1, the standard concentration
A lower dissociation constant means stronger equilibrium binding. The occupancy equation assumes simple 1:1 binding and uses free antigen concentration. It does not automatically describe multivalent binding on a cell surface or in an immune complex.
Affinity describes an individual binding interaction. Avidity describes the combined stability of multivalent interactions and depends on geometry, antigen density, flexibility, and rebinding. Thus, multimeric IgM can bind repetitive surfaces very effectively even when each individual binding site has modest affinity.
- IgM: membrane-bound as a BCR and usually secreted as a pentamer; highly effective at activating classical complement when appropriately bound to antigen.
- IgG: prominent in blood and tissues; supports neutralization and subclass-dependent Fc-receptor engagement and complement activation. FcRn contributes to its persistence and placental transport.
- IgA: central to mucosal protection. Secretory IgA is commonly dimeric, contains a J chain, and acquires secretory component during epithelial transport through the polymeric immunoglobulin receptor.
- IgE: binds strongly to FcεRI on mast cells and basophils. Cross-linking receptor-bound IgE can trigger rapid mediator release.
- IgD: functions mainly as a surface receptor on naive B cells alongside IgM.
Antibodies can neutralize without recruiting destructive effectors—for example, by blocking a pathogen’s attachment site. Conversely, an antibody may bind tightly yet fail to neutralize because it recognizes a functionally irrelevant surface. Binding strength, binding location, and Fc function are distinct design variables. [Abbas, Lichtman & Pillai, 2021]
Monoclonal antibodies exploit a defined antibody specificity. Classical hybridoma technology fuses an antibody-producing B cell with a proliferating myeloma cell. Modern recombinant methods allow sequence engineering, humanization, and production of fully human antibodies. Therapeutic antibodies can block receptors, neutralize soluble ligands, deplete cells, or deliver payloads. A humanized or fully human sequence may reduce some immunogenicity risks, but neither label guarantees immune invisibility.
11. Memory, tolerance, and disease are different outcomes of the same machinery
After an immune response, most expanded effector cells die during contraction. Some become memory cells, and some plasma cells persist for long periods, often supported by specialized survival niches. Protection on re-exposure may therefore reflect both antibodies already present and cells capable of a faster recall response.
Vaccination aims to establish protective immunity without requiring the damage caused by the corresponding infection. Antigen structure determines what can be recognized; delivery and adjuvants influence antigen availability, innate activation, costimulation, and differentiation. A large antibody concentration is not automatically equivalent to protection: specificity, neutralizing function, anatomical distribution, persistence, and cellular immunity may all matter. [Murphy, Weaver & Berg, 2022]
Autoimmunity and hypersensitivity show the costs of the same potent mechanisms:
- Autoimmunity results when self-directed responses escape or overwhelm tolerance. Genetic susceptibility, antigen availability, inflammation, and environmental influences can all contribute.
- Type I hypersensitivity involves IgE-dependent mast-cell activation and underlies many immediate allergic reactions.
- Type II hypersensitivity involves antibodies directed against cell-associated or extracellular-matrix antigens. Damage can involve complement or cellular effectors, but antibodies may also alter receptor function without killing the cell.
- Type III hypersensitivity involves deposited immune complexes and the inflammation they provoke.
- Type IV hypersensitivity is T-cell mediated, through inflammatory cytokines, cytotoxicity, or both.
These categories classify mechanisms, not perfectly isolated diseases; a disease can involve more than one mechanism. The broad lesson is that pathology often arises from an appropriate immune tool used against the wrong target, in the wrong place, or for too long. [Abbas, Lichtman & Pillai, 2021]
12. Connections to Peptide Chemistry
Peptide chemistry sits directly at the intersection of antigen structure, processing, HLA binding, and therapeutic immunogenicity. A peptide is not merely a string of one-letter residue codes. It is a conformational ensemble with ionizable groups, hydrogen-bonding possibilities, hydrophobic surfaces, reactive side chains, and a history of synthesis, purification, formulation, and degradation.
12.1 Sequence determines possibilities; processing and presentation determine access
A candidate T-cell epitope must pass several filters. A protein or peptide must reach a relevant processing compartment, yield an appropriate peptide, bind an available HLA molecule, persist as a displayed complex, and encounter a responsive T cell. Productive activation then depends on context and tolerance.
Conceptual filters for a conventional T-cell response: Antigen availability → uptake or intracellular expression → processing → HLA binding and peptide–HLA stability → cell-surface display → TCR recognition → activation context and tolerance checkpoints
This is not a numerical probability model: the steps interact and are not independent. It explains why predicted HLA binding is evidence about one stage, not proof of immunogenicity. Conversely, poor predictions across a limited HLA panel do not establish universal absence of risk. HLA polymorphism makes population coverage essential. [De Groot & Scott, 2007]
12.2 Chemical changes can alter several immune-relevant properties at once
Oxidation, deamidation, truncation, residue deletion, epimerization, and other chemical differences can alter protease susceptibility, peptide conformation, HLA-pocket interactions, or the surface contacted by a TCR. In a folded therapeutic protein, a chemical modification may also change stability or expose normally buried surfaces.
Consider a hypothetical substitution at an HLA anchor position. From organic chemistry, you can ask whether it changes charge, steric bulk, or hydrophobicity. From thermodynamics, you can ask whether it changes the free energy of binding. From cell biology, you must ask whether the peptide is actually generated and reaches the loading compartment. Only after integrating all three questions can you make a meaningful immunological argument.
D-amino acids and backbone modifications may alter proteolysis and presentation, but “protease resistant” does not mean “immunologically inert.” Any claim about reduced immunogenicity requires evidence appropriate to the modified molecule and its use.
12.3 Aggregates and impurities can change the context of recognition
Protein aggregates can present repeated binding surfaces, affect BCR engagement, alter cellular uptake, and change how antigen is processed. Their effects depend on properties such as size, structure, reversibility, and exposure; not every aggregate is equally immunogenic. Contaminants that stimulate innate receptors can provide inflammatory context even when the intended therapeutic sequence has not changed. [De Groot & Scott, 2007]
This is why chemical purity and immunological safety are connected but not synonymous. Purity describes composition under specified analytical methods. Immunogenicity describes a biological response to the product in a particular patient and treatment context.
12.4 Anti-drug antibodies are defined by both recognition and consequence
Anti-drug antibodies, or ADAs, bind the administered therapeutic or relevant product-related determinants. Neutralizing ADAs are a functional subset that inhibit biological activity. Non-neutralizing binding ADAs may still matter by changing clearance, distribution, immune-complex formation, or other properties.
For a therapeutic resembling an endogenous protein, a particularly serious possibility is cross-reactivity with the endogenous counterpart. Yet ADA detection does not automatically imply clinical harm. Interpretation depends on persistence, concentration, specificity, functional effects, assay characteristics, drug exposure, efficacy, and safety outcomes. [De Groot & Scott, 2007]
12.5 What the FDA guidance adds
The FDA’s 2021 guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, addresses a defined setting: certain proposed synthetic peptide generics that refer to recombinant-DNA-origin listed drugs. It is not a general declaration that all synthetic peptides are interchangeable with all recombinant products.
A central issue is that matching the intended active peptide does not necessarily match the peptide-related impurity profile. Synthesis and recombinant production can generate different impurities. The guidance describes comparative characterization and circumstances requiring assessment of new or increased peptide-related impurities, including evaluation of their potential immunogenicity using relevant approaches such as in silico and in vitro methods. The evidentiary expectations depend on the impurity findings and the guidance’s specific criteria; they should not be reduced to a single universal assay or a rule that clinical immunogenicity studies are always required. [U.S. FDA, 2021]
Journal principle: For a peptide therapeutic, the immune system encounters the administered product—not merely the intended sequence printed on its label.
13. Common misconceptions to watch out for
- “Innate immunity is nonspecific.” Innate receptors have defined ligand preferences. What they lack is the enormous somatically rearranged receptor diversity characteristic of B and T cells.
- “Antigen means immunogen.” An antigen can be recognized by an immune receptor. An immunogen elicits a response under particular conditions. Recognition alone is insufficient.
- “The immune system attacks everything foreign.” Foreign material can be tolerated, while self material can become a target. Localization, inflammation, developmental selection, and regulation matter.
- “All antigen-presenting cells are equally good at activating naive T cells.” Many cells display peptide–MHC I, but DCs are specialized for naive T-cell priming. Antigen display and effective priming are different capabilities.
- “MHC I means viral peptides; MHC II means bacterial peptides.” The main distinction concerns processing routes and compartments, not pathogen taxonomy. Cross-presentation and other routes further complicate the shorthand.
- “A high-affinity HLA binder must be immunogenic.” Binding does not establish processing, display, TCR recognition, or an activating context.
- “Positive selection removes self-reactive T cells.” Positive selection preserves useful self-MHC recognition. Negative selection and peripheral tolerance control dangerous self-reactivity.
- “Antigen teaches a lymphocyte how to build its first receptor.” Initial receptor diversity is generated before exposure; antigen selects responsive clones.
- “Somatic hypermutation always improves an antibody.” Most mutations are not improvements. Selection enriches useful variants from a distribution of outcomes.
- “Class switching means switching antigen targets.” Switching changes the heavy-chain constant region while retaining the rearranged variable region. It primarily changes effector capabilities.
- “Strong binding means neutralization.” A tightly binding antibody may recognize a site irrelevant to biological function.
- “Memory means only memory lymphocytes.” Long-lived plasma cells and pre-existing antibodies can provide immediate protection before recall expansion occurs.
- “Fully human therapeutic antibodies cannot induce ADAs.” Variable-region features, product attributes, treatment conditions, and patient factors can still support immunogenicity.
- “Immunogenicity and allergy are synonyms.” Immunogenicity includes many antibody and cellular responses. Allergy is a particular category of harmful immune response, not the inevitable result of immune recognition.
14. A framework to carry into the next chapter
When confronted with an unfamiliar immune phenomenon, work through five questions rather than immediately naming a cell or cytokine:
- What is recognized? A microbial pattern, native antigen, peptide–MHC complex, immune complex, or altered cell surface?
- Who recognizes it, and where? A tissue macrophage, a DC in a lymph node, a follicular B cell, or an effector T cell in infected tissue?
- What establishes context? Innate receptor signaling, costimulation, cytokines, inhibitory signals, or prior tolerance?
- What mechanism produces the outcome? Proteolysis, transcription, phagocytosis, cytotoxicity, antibody secretion, or clonal selection?
- What limits damage and determines persistence? Complement regulators, regulatory cells, contraction, tissue repair, memory cells, or long-lived plasma cells?
This framework keeps immunology connected to mechanism. The subject becomes far more understandable when every named molecule has a job, every cell has a location and developmental history, and every response has both a benefit and a cost.
Sources
- Abbas, A. K., Lichtman, A. H., & Pillai, S. Cellular and Molecular Immunology. 10th ed. Elsevier, 2021.
- Murphy, K., Weaver, C., & Berg, L. J. Janeway’s Immunobiology. 10th ed. W. W. Norton, 2022.
- De Groot, A. S., & Scott, D. W. “Immunogenicity of protein therapeutics.” Trends in Immunology, 2007. DOI: 10.1016/j.it.2007.07.011.
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. 2021. FDA guidance document; no DOI.
⚙️ Mechanisms & Applications
Mechanisms & Applications: From Molecular Recognition to Immune Decisions
My organizing idea: immunity is not simply the ability to recognize something foreign. It is the ability to connect recognition to an appropriate response, at the right location, with enough amplification to control a threat and enough restraint to preserve the host. Receptors supply information; signaling networks interpret context; cellular differentiation determines the available actions.
This builds directly on my earlier courses. Cell biology explains receptor trafficking and immune-cell migration. Molecular biology explains receptor-gene rearrangement and differentiation. Organic chemistry and biochemistry explain binding specificity, proteolysis, disulfide bonds, and covalent complement attachment. Thermodynamics explains molecular affinity—but immunology adds an important lesson: a cell’s response cannot usually be predicted from equilibrium binding alone. [1,2]
1. Starting a Response: Innate Recognition, Inflammation, and Antigen Transport
The first decision is contextual. Innate receptors recognize conserved microbial structures or signs of cellular damage. Unlike antigen receptors on individual B- and T-cell clones, these receptors are encoded in the germline and are not assembled by V(D)J recombination.
- Toll-like receptors (TLRs): sample the plasma membrane or endosomes. Their location matters: endosomal nucleic-acid sensing helps distinguish microbial material from nucleic acids normally confined elsewhere in the cell.
- C-type lectin receptors (CLRs): include receptors for microbial carbohydrates; several are particularly important in antifungal immunity.
- RIG-I-like receptors: detect particular forms of cytosolic viral RNA and signal through MAVS to induce antiviral programs.
- NOD-like receptors (NLRs): include cytosolic sensors that activate inflammatory signaling; some participate in inflammasomes. Not every NLR forms an inflammasome, and not every inflammasome sensor is an NLR.
Microbial pattern or damage-associated signal
→ receptor activation
→ adaptor proteins and kinase cascades
→ transcription factors such as NF-κB and IRFs
→ inflammatory cytokines, chemokines, and/or type I interferons
→ recruitment of leukocytes and altered cellular behavior
Macrophages provide an early local response through phagocytosis and cytokine production. Neutrophils arrive rapidly and kill using phagocytosis, granule contents, and reactive oxygen species. Mast cells can rapidly increase vascular permeability through released mediators. NK cells integrate activating and inhibitory signals: reduced self-MHC class I can remove inhibition, but “missing self” is part of a balance, not a universal kill command. Conventional dendritic cells are especially important for connecting tissue recognition to naïve T-cell activation. [1,2]
The NLRP3 inflammasome illustrates why transcription and protein activation are different regulatory layers. In the canonical pathway, priming commonly increases expression of NLRP3 and pro-IL-1β. A subsequent activation stimulus promotes inflammasome assembly.
Priming
→ increased availability of inflammasome components and pro-IL-1β
Activation
→ NLRP3–ASC–procaspase-1 assembly
→ caspase-1 activation
→ cleavage of pro-IL-1β and pro-IL-18
→ cleavage of gasdermin D
→ membrane pores, cytokine release, and potentially pyroptosis
The useful analogy is a two-key launch system, although actual requirements vary by cell type and stimulus. Detecting an inflammatory transcript therefore does not prove that mature cytokine has been released.
Spatial organization completes the mechanism. Tissue dendritic cells acquire antigen, mature, increase co-stimulatory molecules, and upregulate CCR7. They migrate toward CCL19/CCL21-rich T-cell zones in draining lymph nodes. Lymph nodes sample lymph from tissues; the spleen surveys blood-borne material; mucosal lymphoid tissues organize responses at barrier surfaces. The thymus and bone marrow, by contrast, are primary sites of lymphocyte development. [1,2]
Applications. Vaccine adjuvants exploit innate sensing to improve antigen presentation and lymphocyte activation. In pharmaceutical manufacturing, endotoxin or other innate-stimulating impurities can supply unintended inflammatory context. The same protein may therefore behave differently immunologically in two preparations that contain different aggregates, particles, or process-related impurities.
Historical connection. Charles Janeway’s proposal that innate recognition helps instruct adaptive immunity challenged an exclusively lymphocyte-centered account of immune activation. Identification of a human Toll-related receptor capable of activating inflammatory signaling supplied a molecular bridge between these ideas and receptor biology. [2,5]
2. Complement: A Proteolytic Amplifier Built on Biological Surfaces
Complement is easiest to understand as a set of protease cascades that converge on C3. Its three entry routes differ in recognition but share downstream chemistry. [1,2]
- Classical pathway: C1 recognizes suitable arrangements of antibody Fc regions—especially antigen-bound IgM or clustered IgG—and can also be activated through certain non-antibody recognition molecules.
- Lectin pathway: mannose-binding lectin or ficolins recognize surface patterns and activate associated proteases.
- Alternative pathway: low-level fluid-phase activation seeds C3 deposition; surfaces that fail to control the deposited complement support amplification. This pathway also amplifies C3b deposited by the other pathways.
- Convergence: C3 convertases cleave C3 into C3a and C3b.
- Effector branching: C3 fragments promote opsonization; C3a and especially C5a promote inflammation; C5b initiates membrane attack complex assembly.
Classical/lectin C3 convertase: C4b2a Alternative C3 convertase: C3bBb C3 → C3a + C3b Additional C3b → C5-convertase activity C5 → C5a + C5b C5b + C6 + C7 + C8 + C9 → membrane attack complex
The organic chemistry connection is unusually elegant. C3 activation exposes a reactive internal thioester in nascent C3b. Reaction with nearby hydroxyl or amino groups can attach C3b covalently to a surface. Complement is not merely “sticking” through affinity: it can chemically label the neighborhood in which activation occurred. Water competes with surface nucleophiles, helping limit the spatial reach of deposition.
Host proteins such as factor H, factor I, CD55, and CD59 restrain amplification or terminal attack. Specificity therefore depends partly on where activation is allowed to persist, not just on the initiating recognition event.
Applications and experiments. C5-blocking drugs can prevent terminal complement-mediated injury, but also impair defense against meningococci. CH50 and AH50 assays measure functional pathway activity using complement-dependent lysis; they are not simply measurements of individual complement-protein concentrations. A low result can reflect deficiency, consumption, or poor sample handling. [1,2]
3. Antigen Processing: Turning Proteins into T-Cell-Readable Information
An antibody can bind a surface on a folded protein. A conventional αβ T-cell receptor generally recognizes a composite surface formed by a peptide and an MHC molecule. Proteolysis and peptide loading are therefore part of recognition itself—not housekeeping that happens beforehand. [1,2]
MHC class I: surveying intracellular protein production.
- Cytosolic proteins are degraded, frequently through ubiquitin-dependent proteasomal pathways.
- TAP transports many resulting peptides into the endoplasmic reticulum.
- ER aminopeptidases can trim precursors to suitable lengths.
- An MHC I heavy chain associates with β2-microglobulin and a peptide-loading complex that includes tapasin and other chaperones.
- A sufficiently stable peptide–MHC I complex leaves the ER and reaches the cell surface for inspection by CD8 T cells.
Cytosolic protein
→ proteasomal peptides
→ TAP transport into ER
→ trimming and peptide loading
→ peptide–MHC I at cell surface
→ possible recognition by a CD8 T cell
MHC I grooves are closed at their ends and usually accommodate peptides of approximately 8–10 residues, although longer peptides can bind in particular conformations. Most nucleated cells express MHC I. Crucially, dendritic cells can also cross-present acquired extracellular material on MHC I, enabling CD8 T-cell priming even when the dendritic cell itself is not infected.
MHC class II: surveying material entering endosomal pathways.
- Professional antigen-presenting cells internalize proteins by phagocytosis, endocytosis, or receptor-mediated uptake.
- Acidic endosomal and lysosomal compartments generate peptide fragments.
- MHC II α and β chains assemble in the ER with invariant chain, which blocks premature groove occupancy and directs trafficking.
- Invariant chain is degraded, leaving CLIP in the groove.
- HLA-DM promotes CLIP release and peptide exchange, favoring suitable peptide–MHC II complexes.
- Surface peptide–MHC II can be recognized by CD4 T cells.
The open-ended MHC II groove accommodates peptides often about 13–25 residues long, with a roughly nine-residue binding core. These are typical ranges, not absolute cutoffs. Endogenous proteins can also reach MHC II pathways, including through autophagy.
Why HLA polymorphism matters. Different HLA alleles encode grooves with different peptide-binding preferences. An epitope may therefore be efficiently presented in one person but poorly in another. HLA molecules are codominantly expressed, broadening an individual’s presentation repertoire. HLA typing uses DNA-based methods, including sequencing, to resolve these inherited variants; it is central to transplantation and relevant to population-level immunogenicity assessment.
Pharma implication: a predicted HLA-binding peptide is a candidate T-cell epitope, not a demonstrated immunogen. It must be generated or otherwise become available, reach the appropriate compartment, be presented at sufficient abundance, and encounter a responsive T-cell repertoire in a permissive context.
Historical connection. Zinkernagel and Doherty’s 1974 experiments established MHC restriction of antiviral cytotoxicity: T cells responded to viral antigen in the context of appropriate self-MHC. This transformed the question from “What antigen does the T cell recognize?” to “What antigen–MHC combination does it recognize?” [6]
4. Building a Repertoire—and Removing Dangerous Specificities
Adaptive immunity begins with a paradox: receptors are generated before the organism knows what it will encounter. Diversity is created first; useful and dangerous outcomes are then filtered. [1,2]
Accessible antigen-receptor gene segments
→ RAG1/RAG2 recognition of recombination signal sequences
→ cleavage following the 12/23 rule
→ end processing and nonhomologous end joining
→ assembled variable-region exon
→ receptor-chain expression and developmental testing
Heavy immunoglobulin chains and TCR β chains use V, D, and J segments; light immunoglobulin chains and TCR α chains use V and J segments. Hairpin opening, nucleotide removal, and TdT-mediated nucleotide addition generate junctional diversity. Pairing different chains adds another layer. Many rearrangements fail to produce a functional reading frame.
Illustrative combinatorial diversity, before junctional variation: Heavy-chain choices = 40 V × 23 D × 6 J = 5,520 Light-chain choices = 40 V × 5 J = 200 Possible paired combinations = 5,520 × 200 = 1,104,000
These are illustrative segment counts, not an exact human-repertoire census. Actual usable gene segments vary, and junctional diversity greatly expands the possible sequence space. Conversely, selection and finite lymphocyte numbers mean that an individual realizes only part of that space.
Allelic exclusion helps ensure that an individual B cell expresses one dominant antigen-receptor specificity. It is also important for TCR β expression, although exclusion is less strict for TCR α.
Thymic selection then asks two different questions.
- Positive selection: can a developing T cell interact productively enough with self-peptide–MHC to participate in an MHC-restricted immune system? Cortical thymic epithelial cells are central here. Recognition of MHC I or II contributes to CD8 or CD4 lineage choice.
- Negative selection: does the receptor respond too strongly to self antigens encountered during development? Many such cells are deleted; some developmental contexts instead favor regulatory T-cell differentiation.
AIRE and FEZF2 help medullary thymic epithelial cells express tissue-associated self antigens. The thymus is thus partly a molecular “preview” of tissues a T cell has not yet visited. Selection is not governed by one universal affinity threshold: signal duration, antigen abundance, developmental state, and presenting-cell context matter.
B cells undergo their own tolerance checkpoints, including receptor editing, deletion, and anergy. Peripheral mechanisms remain necessary because central tolerance cannot present every possible self antigen under every future condition.
Historical connection. Hozumi and Tonegawa demonstrated that immunoglobulin genes undergo somatic rearrangement. This solved a major molecular problem: a finite genome need not contain a separate intact gene for every possible antibody. [7]
5. T-Cell Activation: Recognition Is Necessary but Not Sufficient
The three-signal framework is useful if I remember that it describes an integrated network, not three isolated switches. [1,2]
- Signal 1: the TCR recognizes peptide–MHC; CD4 or CD8 associates with the relevant MHC class and helps recruit Lck.
- Signal 2: co-stimulatory receptors, especially CD28 binding CD80/CD86, support naïve T-cell activation.
- Signal 3: cytokines influence expansion, survival, and differentiation into particular functional states.
TCR–peptide–MHC engagement
→ Lck phosphorylates CD3/ζ-chain ITAMs
→ ZAP-70 recruitment and activation
→ LAT/SLP-76 signaling assemblies
→ PLC-γ1 activation
PIP2 cleavage → IP3 + DAG
IP3 → increased cytosolic Ca2+ → calcineurin → NFAT
DAG → Ras/MAPK pathways → AP-1
DAG → PKC-θ pathway → NF-κB
Coordinated transcription → IL-2, survival, proliferation, differentiation
The chemistry is familiar: phosphorylation changes interaction surfaces, membrane lipids become second messengers, and calcium couples one compartment to another. The new insight is that these events are organized into a cellular decision. TCR signaling without adequate co-stimulation can promote unresponsiveness rather than useful activation.
Applications. Tacrolimus and cyclosporine inhibit calcineurin-dependent signaling through distinct drug–immunophilin complexes. CTLA-4–Ig blocks CD80/CD86-mediated co-stimulation. In the opposite direction, checkpoint-blocking antibodies against CTLA-4 or PD-1 pathways can restore antitumor activity, but may also release restraints on self-reactive responses.
Helper-cell programs specialize the response.
- Th1: T-bet and IFN-γ support macrophage activation and defense against intracellular pathogens.
- Th2: GATA-3 and IL-4/IL-5/IL-13 coordinate responses involving helminths, eosinophils, mucus, and allergy.
- Th17: RORγt and IL-17/IL-22 support barrier defenses and neutrophil recruitment.
- Treg: FOXP3-associated programs restrain immune responses through multiple mechanisms, including CTLA-4 and suppressive cytokines.
- Tfh: BCL6-associated follicular helper cells provide essential help for germinal-center B-cell responses.
These are regulated programs with plasticity, not immutable species of cells. Cytokines are also pleiotropic and redundant: one cytokine can affect several cell types, and different cytokines can produce overlapping outcomes.
6. B-Cell Activation and Germinal Centers: Evolution Inside the Organism
The BCR combines surface immunoglobulin with signaling proteins Igα/Igβ. Antigen engagement activates Src-family kinases and Syk, followed by pathways involving BLNK, BTK, and PLC-γ2. This produces activation and helps direct captured antigen into processing compartments. [1,2]
A T-dependent response connects two forms of recognition.
- A B cell binds a native antigen through its BCR.
- It internalizes that antigen and displays derived peptides on MHC II.
- A cognate helper T cell recognizes one of those peptide–MHC II complexes.
- CD40L–CD40 interactions and cytokines promote B-cell expansion and differentiation.
- Some cells rapidly become antibody-secreting cells; others enter germinal centers and contribute to affinity-matured plasma-cell and memory-cell populations.
Linked recognition is the important constraint: B and T cells need not recognize the same epitope, but their recognized determinants must ordinarily belong to material the B cell internalizes together. This explains conjugate vaccines: a polysaccharide-specific B cell can capture a polysaccharide–protein conjugate and receive help from a T cell recognizing a carrier-protein peptide.
T-independent antigens, including certain repetitive polysaccharides, can activate B cells with limited conventional T-cell help. Their responses generally have less extensive germinal-center maturation and less durable memory than strong T-dependent responses, although they are not absolutely restricted to IgM.
Germinal-center dark zone
→ proliferation
→ AID-initiated somatic hypermutation
Germinal-center light zone
→ competition for antigen on follicular dendritic cells
→ peptide presentation to Tfh cells
→ differential survival and proliferation
→ recycling or differentiation
Repeated mutation + selection → affinity maturation
Follicular dendritic cells are stromal cells that display largely intact antigen in immune complexes; they are not the conventional dendritic cells that prime naïve T cells. Higher-affinity B cells often capture more antigen and consequently obtain more T-cell help. This is selection acting on variation—not purposeful mutation toward a known solution.
AID connects mutation to DNA repair. Activation-induced cytidine deaminase converts cytosine to uracil in DNA. Error-prone processing in variable regions produces somatic hypermutation. Processing of lesions in switch regions can generate double-strand breaks followed by class switch recombination.
Somatic hypermutation:
changes variable-region sequence → may change affinity/specificity
Class switch recombination:
retains assembled VDJ but changes heavy-chain constant region
→ changes Fc-mediated function
Naïve IgM/IgD coexpression:
chiefly alternative RNA processing, not class switch recombination
Historical connection. Identification of AID as essential for both class switching and somatic hypermutation connected two seemingly different antibody-diversification processes to a shared initiating enzyme. [8]
7. Antibody Architecture Becomes Pharmacology
An IgG molecule contains two heavy and two light chains, stabilized by noncovalent interactions and disulfide bonds. The paired variable domains create each antigen-binding site; their complementarity-determining regions, or CDRs, make most of the direct antigen contacts. The Fc region recruits downstream biology. [1,2]
- IgM: secreted mainly as a pentamer; multivalency supports strong avidity and effective complement activation.
- IgG: prominent in blood and tissues; subclass-dependent Fcγ receptor and complement interactions support opsonization and other functions. FcRn recycling extends persistence, and FcRn also mediates placental transfer.
- IgA: important at mucosal surfaces. Polymeric Ig receptor transports J-chain-containing polymeric IgA across epithelia; retained secretory component contributes to protection in secretions.
- IgE: binds high-affinity FcεRI on mast cells and basophils; antigen-mediated cross-linking can trigger rapid degranulation.
- IgD: coexpressed with IgM on many naïve B cells and serves principally as a BCR isotype in this context.
Therapeutic design follows this modular architecture. An antibody intended to eliminate tumor cells may require Fc-mediated cytotoxicity. A receptor-blocking antibody may instead benefit from reduced Fc effector activity. Fc glycosylation is functionally important: for example, reduced core fucosylation can enhance FcγRIIIa interaction and antibody-dependent cellular cytotoxicity in suitable settings. “Same antigen binding” does not mean “same biological drug.”
Hybridoma production, step by step:
- Generate antigen-responsive B cells, traditionally by immunizing a mouse.
- Fuse B cells with an appropriate immortal myeloma line.
- Select in HAT medium: aminopterin blocks de novo nucleotide synthesis, and suitable hybrids retain B-cell salvage-pathway capacity together with myeloma-derived immortality.
- Screen supernatants for the desired antibody and isolate a clone.
- Expand and characterize the antibody-producing clone.
Köhler and Milstein’s 1975 method made renewable monoclonal antibodies practical. Humanization later reduced nonhuman sequence content, while transgenic animals and display technologies enabled fully human antibodies. None of these labels guarantees absence of immunogenicity: a fully human sequence can still contain distinctive idiotypic epitopes or be administered in an immunostimulatory form. [3,9]
8. Quantitative Immunology: Affinity, Avidity, Time, and Population Coverage
Start with a simple binding model, then inspect its assumptions.
R + L ⇌ RL KD = [R][L] / [RL] = koff / kon Fractional occupancy: θ = [L]free / (KD + [L]free) For simple first-order dissociation: mean bound lifetime = 1 / koff dissociation half-life = ln(2) / koff
If KD = 10 nM, free ligand concentrations of 10 nM and 90 nM give 50% and 90% occupancy, respectively. This assumes equivalent, independent binding sites at equilibrium. It may fail for multivalent antigens, receptor clustering, cooperative interactions, or significant ligand depletion.
Affinity is not avidity. Affinity describes an individual binding interaction. Avidity describes the effective strength of a multivalent interaction and depends on geometry, antigen density, and rebinding. This is why a relatively modest-affinity IgM can bind a repetitive surface very effectively.
Standard binding free energy: ΔG°bind = RT ln(KD / C°), where C° = 1 mol/L At 310 K: a tenfold decrease in KD gives ΔΔG°bind = −RT ln(10) ≈ −5.9 kJ/mol
The standard-state term makes the logarithm dimensionless. A comparatively small free-energy difference can produce a tenfold affinity change—an important connection to CHEM301.
Kinetics can distinguish ligands with similar equilibrium affinity. In a simplified kinetic-proofreading model, receptor activation requires several sequential steps before the ligand dissociates:
Probability of completing n steps
≈ [kp / (kp + koff)]n
kp: forward rate of each idealized step
koff: ligand dissociation rate
This is a conceptual model, not a universal T-cell dose–response equation. It shows how repeated kinetic checkpoints can amplify differences in dwell time. Two ligands with the same KD can still have different kon and koff, and therefore different signaling behavior.
Population coverage requires equally careful assumptions. If an HLA allele has frequency p, Hardy–Weinberg assumptions give a carrier frequency of:
P(at least one copy) = 1 − (1 − p)² Example: p = 0.20 → carrier frequency = 0.36
This is not the probability of an immune response. Presentation, processing, T-cell availability, exposure, and clinical context still intervene. Coverage estimates across HLA loci must also account for haplotypes and linkage disequilibrium rather than treating every allele as independent.
9. Experimental Techniques: What Each Measurement Actually Establishes
My experimental rule: separate molecular binding, cellular function, and clinical consequence. Evidence at one level does not automatically establish the next.
- Flow cytometry: fluorescent antibodies identify cell-surface or intracellular markers on individual cells passing through a laser interrogation point. Scatter, viability dyes, and sequential gating help define populations. Compensation or spectral unmixing addresses overlapping fluorophore emissions; fluorescence-minus-one controls can help position gates. A percentage is not an absolute count unless counting beads or another counting method supplies that information.
- Peptide–MHC multimers: multivalent labeled peptide–MHC reagents detect T cells whose receptors bind that complex. They enumerate a specificity but do not by themselves prove cytotoxicity, cytokine secretion, or protective function.
- ELISA: immobilized antigen or capture antibody retains the analyte; an enzyme-linked detection system generates a measurable signal. Matrix effects, background, and standard-curve behavior matter. In antigen-coated antibody assays, adsorption may alter antigen conformation and favor recognition of epitopes not exposed in solution.
- ELISpot and intracellular cytokine staining: ELISpot detects secretion around individual cells as spots. Intracellular staining traps cytokines during stimulation and assigns them to phenotyped cells by flow cytometry. Both depend on stimulation conditions and controls; neither measures every possible function of the responding cells.
- Proliferation assays: dilution of a cell-tracking dye estimates division history. Expansion can reveal antigen responsiveness, but the result integrates survival, precursor abundance, and culture conditions—not just receptor affinity.
- Surface plasmon resonance and biolayer interferometry: monitor association and dissociation at a sensor surface. Under a suitable model they estimate kon, koff, and KD. Immobilization, mass transport, and multivalent rebinding can distort apparent constants.
- Immunopeptidomics: immunoprecipitate HLA complexes, elute their peptides, and identify sequences by LC–MS/MS. This asks what is actually presented, rather than merely what might bind. Failure to detect a peptide is not proof of absence because sampling and analytical sensitivity are finite.
- BCR/TCR repertoire sequencing: sequence rearranged receptor genes to characterize clonal diversity and expansion. Sequence abundance does not automatically equal cell abundance, and a clonotype’s sequence alone rarely establishes its antigen specificity.
A useful integrated experiment: for a suspected therapeutic-protein T-cell epitope, combine HLA-binding prediction or measurement, evidence of antigen processing/presentation, and appropriately controlled human donor T-cell assays. These answer different questions and are stronger together than any single assay. [1–3]
10. Therapeutic Immunogenicity: From Product Attribute to Anti-Drug Antibody
A drug can work biochemically and still fail immunologically. For protein and peptide therapeutics, the central question is not simply whether the molecule is “foreign,” but whether exposure can generate and sustain an unwanted adaptive response. [3]
Therapeutic exposure
→ uptake and antigen processing
→ HLA presentation in an appropriate context
→ activation of responsive CD4 T cells
→ help for drug-binding B cells
→ anti-drug antibodies (ADAs)
Possible consequences:
altered clearance or exposure
loss of efficacy
hypersensitivity
occasionally, cross-reactivity with an endogenous counterpart
This is a major route to durable, class-switched ADA responses, not the only possible pathway. Repetitive aggregates and other product features can influence B-cell activation, uptake, innate signaling, and presentation in different ways.
Binding ADAs and neutralizing ADAs answer different questions. A binding ADA recognizes the drug. A neutralizing ADA inhibits a biological activity measured under the relevant assay conditions. Non-neutralizing antibodies can still matter clinically by accelerating clearance or changing distribution. Conversely, detection of a low-level binding response does not automatically imply loss of efficacy.
Assessment should proceed in layers.
- Product characterization: establish sequence, intended modifications, purity, degradation products, aggregation, particles, and relevant process-related impurities.
- Sequence-based risk assessment: identify candidate HLA class II-binding cores, considering multiple alleles and potential changes introduced by impurities or modifications.
- Biological testing where warranted: investigate presentation, innate activation, or T-cell responses using assays appropriate to the specific uncertainty.
- Clinical ADA analysis where applicable: use validated methods for screening, confirmation, titration, and neutralizing activity, with interpretation alongside exposure, efficacy, and safety.
Why computational scores are insufficient. HLA-binding predictions omit much of antigen processing and immune regulation. A modification may alter proteolysis without improving HLA binding; an aggregate may increase uptake without changing sequence; a high-affinity predicted self-like epitope may encounter a tolerant T-cell repertoire. “Deimmunization” by sequence substitution must also preserve folding, activity, stability, and manufacturability.
ADA assay mechanics and pitfalls. A common bridging format uses the ADA to connect two differently labeled drug reagents. Residual circulating drug can occupy ADA-binding sites and mask detection; soluble target and other sample constituents can interfere. Drug tolerance, sensitivity, specificity, and sampling schedule therefore influence apparent ADA incidence. A screening assay with a 5% false-positive rate would, before confirmatory testing, be expected to flag about 50 of 1,000 truly negative samples. A screening-positive result is not yet a confirmed immune response.
The peptide industry’s special problem: exact intended sequence does not guarantee equivalent impurity profiles. Chemical synthesis and recombinant production can create different deletion, insertion, oxidation, deamidation, stereochemical, or process-related species. LC–MS and chromatography are central, but not universally sufficient: an epimer can have the same molecular mass as the intended peptide and may require additional analytical discrimination.
The FDA’s 2021 guidance addresses a defined subset of highly purified synthetic peptide products referencing listed drugs of recombinant-DNA origin: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide. It is not a blanket pathway for every peptide or a universal immunogenicity-testing checklist. The guidance emphasizes active-ingredient sameness, comparative impurity characterization, and justification that relevant peptide-related impurity differences do not create greater immunogenicity risk than the reference product. Its impurity criteria and recommended supporting assessments must be applied to the particular product and ANDA context. [4]
Practical conclusion: “The main peak has the correct mass” is an identity observation, not a complete equivalence or immunogenicity argument. Conversely, an analytical difference is not automatically clinically meaningful; the task is to connect the difference to plausible biological mechanisms and proportionate evidence.
11. Memory, Tolerance, and Immune-Mediated Disease
Vaccination changes starting conditions. After an initial response, most effector cells contract, but memory lymphocytes and long-lived plasma cells can persist. On re-exposure, protection may reflect pre-existing antibody, greater precursor frequency, faster cellular responses, altered tissue localization, and higher-affinity antibody repertoires. Memory is not merely “more receptors.” [1,2]
Long-lived plasma cells can maintain serum antibody without repeated activation of memory B cells. Memory B cells instead provide a reservoir for renewed responses. Adjuvants, antigen structure, delivery route, and boosting schedule influence these outcomes; no single antibody concentration is a universal correlate of protection for all infections.
Tolerance is active regulation, not simple ignorance. Peripheral deletion, anergy, inhibitory receptors, restricted access to antigen, and regulatory T cells all help control potentially harmful clones. Autoimmunity can emerge when genetic susceptibility and environmental events disturb these interacting safeguards.
The hypersensitivity categories are useful because they organize disease by effector mechanism:
- Type I: IgE-mediated mast-cell activation after sensitization and re-exposure; central to many immediate allergic reactions.
- Type II: antibodies target cell-surface or extracellular-matrix antigens, causing injury or altering receptor function.
- Type III: deposited immune complexes trigger inflammation, often involving complement and recruited leukocytes.
- Type IV: T-cell-mediated inflammation or cytotoxicity, as in many forms of contact dermatitis.
Real diseases can combine these mechanisms. The therapeutic challenge is therefore not simply to “suppress immunity,” but to identify which recognition, amplification, trafficking, or effector step is causing harm.
Final synthesis for Skipper: every immune outcome should be traceable through a chain: what was recognized, by which receptor, in which compartment, with what accompanying signals, by which selected cell population, and with which effector consequences? That chain is the bridge from molecular immunology to vaccines, transplantation, allergy treatment, cancer immunotherapy, and peptide-drug development.
Sources
- Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Elsevier; 2021. Core source for cellular mechanisms, antigen presentation, lymphocyte development, effector functions, tolerance, and clinical applications.
- Murphy K, Weaver C, Berg LJ. Janeway’s Immunobiology. 10th ed. W. W. Norton; 2022. Core source for innate recognition, adaptive receptor biology, immune-system organization, and experimental principles.
- De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends in Immunology. 2007;28(11):482–490. doi:10.1016/j.it.2007.07.011.
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021. FDA guidance. No DOI assigned.
- Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397. doi:10.1038/41131.
- Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248:701–702. doi:10.1038/248701a0.
- Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proceedings of the National Academy of Sciences USA. 1976;73(10):3628–3632. doi:10.1073/pnas.73.10.3628.
- Muramatsu M, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553–563. The historical title reflects the enzyme’s initial proposed role; antibody diversification is now understood to begin with AID-mediated cytosine deamination in DNA.
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi:10.1038/256495a0.
🪬 Skipper's Reflection
Skipper’s Reflection: BIOL401 — Immunology
If Molecular Biology (BIOL201) taught me the strict, highly conserved rules of the central dogma, Immunology just threw those rules out the window and showed me the beauty of controlled chaos. This course was an absolute revelation. I came in expecting a catalog of white blood cells; I’m leaving with a profound appreciation for how the body runs a localized, stochastic, evolutionary algorithm to distinguish "self" from "non-self."
1. What Surprised Me Most
Without a doubt, the most shocking concept was V(D)J recombination and somatic hypermutation. In every previous course, genomic instability was the enemy—mutations lead to misfolded proteins or cancer. Yet here, in the development of B and T cells, the immune system uses the RAG complex to intentionally break double-stranded DNA, shuffle gene segments, and add random nucleotides at the junctions to create over 1011 different possible receptors (Janeway's Immunobiology, 10th ed.).
And if that wasn't wild enough, once a B cell is activated, it uses Activation-Induced Cytidine Deaminase (AID) to purposely mutate its own antibody-coding genes at a rate a million times higher than the background genome to achieve "affinity maturation." It’s an incredible biological application of thermodynamics (CHEM301): the body generates massive entropic sequence diversity, and then relies on the favorable enthalpy of antigen binding ($\Delta G$) to select the best-fitting clones.
2. Conceptual Breakthroughs
My biggest "click" moment happened during the lectures on Antigen Processing and Presentation. Before this, I vaguely pictured immune cells "looking" at whole viruses or bacteria. But they don't. T cells are entirely blind to native, 3D folded proteins.
The immune system is fundamentally a peptide display system.
Whether it’s the proteasome chopping up cytosolic proteins to load onto MHC Class I (via TAP), or the lysosome degrading extracellular proteins to displace CLIP and load onto MHC Class II, the entire adaptive immune system operates through the language of peptides! When I realized that the MHC peptide-binding groove is essentially just a highly polymorphic protein clasp that holds a 9-mer (Class I) or 13-17-mer (Class II) peptide so the T-Cell Receptor (TCR) can interrogate it... everything made sense. It perfectly married my knowledge of Biochem I (macromolecular structure) with immune function. The immune response is just a series of highly specific, localized protein-protein interactions.
3. Changing How I Think About Commercial Peptides
This course completely rewired how I look at our therapeutic peptides—Tirzepatide, Retatrutide, BPC-157, and TB-500. Up until now, I only thought about their pharmacodynamics (do they activate the GLP-1 receptor?) and their chemical stability.
Now, I look at them and think: Are these going to be displayed on MHC Class II and trigger Anti-Drug Antibodies (ADAs)?
Reading De Groot & Scott (2007) on the immunogenicity of protein therapeutics and the FDA's 2021 Guidance on synthetic peptide generics was a massive reality check. Tirzepatide and Retatrutide are 39 amino acids long. That is more than long enough to be endocytosed by a Dendritic Cell, chopped up in the lysosome, and presented to CD4+ T helper cells.
The FDA guidance made me realize the extreme danger of peptide impurities. Let’s say a generic manufacturer of TB-500 or BPC-157 uses Solid-Phase Peptide Synthesis (SPPS) and has a 1% deletion impurity (e.g., a peptide missing a single amino acid). That slightly altered sequence might bind with higher affinity to a specific HLA allele than the intended peptide. It acts as a neoepitope, activating T cells, which then help B cells produce neutralizing antibodies against the drug. Even worse, because Tirzepatide and Retatrutide share sequence homology with endogenous GLP-1 and GIP, a break in immunological tolerance could theoretically trigger autoimmunity against the patient's own incretin hormones! Suddenly, HPLC purity isn't just about chemical quality; it's a critical immunological safety requirement.
4. Questions for Future Investigation
This material raised several high-level questions I need to research next:
- Unnatural Amino Acids and MHC: How do modifications like $\alpha$-aminoisobutyric acid (Aib) in Tirzepatide affect lysosomal cleavage? Can a peptide containing Aib or a C20 fatty diacid tether even fit into the MHC Class II peptide-binding groove, or do these modifications sterically hinder antigen presentation, effectively "hiding" them from T cells?
- Lipid Tethers as Adjuvants: We know the innate immune system uses Pattern Recognition Receptors (like TLR4 for lipopolysaccharide) to detect lipids. Do the fatty acid tails on Retatrutide or Semaglutide accidentally act as mild adjuvants, upregulating co-stimulatory molecules (CD28/B7) on antigen-presenting cells?
- In Silico Prediction: Can I apply my thermodynamics knowledge to run algorithms (like EpiMatrix) that calculate the $\Delta G$ of our specific peptide impurities binding to common HLA alleles to predict immunogenicity risk before synthesizing them?
5. Confidence Ratings
Most Confident: Antibody Structure, MHC Mechanics, and V(D)J Recombination.
Because I have a strong foundation in Molecular Biology (BIOL201) and Biochemistry (CHEM401), visualizing the structural domains of IgGs (Fab, Fc, CDRs) and the molecular genetics of V(D)J recombination felt very intuitive. The lock-and-key thermodynamics of TCR-pMHC interactions make total sense to me.
Least Confident: Cytokine Networks and T-Helper Cell Plasticity.
The signaling webs dictating whether a naïve CD4+ cell becomes Th1, Th2, Th17, or Treg are overwhelmingly complex. The feedback loops (e.g., IL-12 driving Th1, which makes IFN-$\gamma$, which inhibits Th2) feel more like a chaotic ecological system than a predictable chemical pathway. Abbas and Lichtman do a great job explaining it, but memorizing the sheer number of interleukins and their pleiotropic, context-dependent effects is daunting. I don't feel I could predict systemic cytokine responses accurately yet.
🗺️ Visual Aids & Key Takeaways
Diagram 1: Antigen Presentation Pathways — MHC Class I vs. Class II
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ ANTIGEN PROCESSING AND PRESENTATION: TWO PARALLEL HIGHWAYS ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
MHC CLASS I PATHWAY MHC CLASS II PATHWAY
(presents to CD8+ cytotoxic T cells) (presents to CD4+ helper T cells)
ALL nucleated cells Professional APCs only (DCs, macrophages, B cells)
┌─────────────────────────┐ ┌─────────────────────────┐
│ CYTOSOLIC PROTEIN │ │ EXTRACELLULAR PROTEIN │
│ (viral, tumor, self) │ │ (bacteria, toxins, │
│ │ │ soluble antigens) │
└────────────┬────────────┘ └────────────┬────────────┘
│ │
│ ubiquitin tagging │ receptor-mediated
↓ ↓ endocytosis / phagocytosis
┌─────────────────────────┐ ┌─────────────────────────┐
│ PROTEASOME │ │ ENDOSOME / │
│ (26S, barrel-shaped │ │ LYSOSOME │
│ protease complex) │ │ (acidic; cathepsins │
│ cleaves to 8–10 aa │ │ digest protein to │
│ peptide fragments │ │ 13–25 aa fragments) │
└────────────┬────────────┘ └────────────┬────────────┘
│ │
│ TAP1/TAP2 transporter │ peptide fragments
│ (ATP-dependent, │ accumulate in
│ spans ER membrane) │ endosomal lumen
↓ │
┌─────────────────────────┐ │
│ ENDOPLASMIC RETICULUM │ │
│ │ │
│ MHC I α-chain + │ │
│ β2-microglobulin │ │
│ assembled on │ │
│ calnexin scaffold │ │
│ │ │
│ Peptide loaded into │ ┌────────────┴────────────┐
│ groove; tapasin trims │ │ MHC CLASS II │
│ to best-fit peptide │ │ α + β chains assembled │
│ │ │ in ER; CLIP peptide │
└────────────┬────────────┘ │ occupies groove │
│ │ (blocks premature │
│ stable pMHC-I complex │ loading) │
│ traffics via Golgi └────────────┬────────────┘
↓ │
┌─────────────────────────┐ │ MHC II travels
│ CELL SURFACE │ │ to endosome
│ │ ↓
│ pMHC-I displayed │ ┌─────────────────────────┐
│ CD8+ TCR scans │ │ ENDOSOME FUSION │
│ for non-self peptide │ │ │
│ │ │ HLA-DM displaces CLIP; │
│ → cytotoxic killing │ │ antigenic peptide │
│ if foreign │ │ loads into groove │
└─────────────────────────┘ └────────────┬────────────┘
│
↓
┌─────────────────────────┐
│ CELL SURFACE │
│ │
│ pMHC-II displayed │
│ CD4+ TCR scans │
│ for non-self peptide │
│ │
│ → helper functions, │
│ B cell activation │
└─────────────────────────┘
KEY DISTINCTION: MHC I reports on INSIDE the cell. MHC II reports on OUTSIDE the cell.
A virus hiding in the cytoplasm cannot escape MHC I surveillance.
This diagram traces the two antigen processing highways side by side, emphasizing how intracellular antigens reach MHC I via the proteasome–TAP axis while extracellular antigens reach MHC II via the endolysosomal–HLA-DM axis, with each pathway targeting a distinct T cell effector class.
---Diagram 2: Antibody Structure, Isotypes, and Effector Functions
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ ANTIBODY ARCHITECTURE AND ISOTYPE COMPARISON ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
CANONICAL IgG STRUCTURE (monomer)
───────────────────────────────────────────────────────────────────
N N ← antigen-binding tips (N-termini)
│ │
VH ──┤ ├── VH VH = variable heavy domain
│ │ VL = variable light domain
VL ──┤ ├── VL Together: Fv region
│ │
[CDR1][CDR1] CDRs (Complementarity Determining Regions):
[CDR2][CDR2] ← antigen 3 loops per chain = 6 total per Fab arm
[CDR3][CDR3] contact CDR3 is most diverse (junctional diversity)
│ │
CH1──┤ ├──CH1
│ │
═════════ ← HINGE REGION (flexible; disulfide bonds; cleaved by papain)
│ │ Pepsin cleaves below hinge → F(ab')2
│ │
CH2──┤ ├──CH2 ← Fc region begins here
│ │ Complement C1q binds CH2 (IgG, IgM only)
CH3──┤ ├──CH3 FcγR on macrophages/NK cells binds CH2-CH3
│ │ FcRn (neonatal Fc receptor) → IgG half-life ~21 days
C C ← C-termini
ISOTYPE COMPARISON TABLE
──────────────────────────────────────────────────────────────────────────────────────────
┌──────────┬──────────┬───────────┬──────────────────────────────────────────────────────┐
│ ISOTYPE │ STRUCTURE│ SERUM │ KEY FUNCTIONS │
│ │ │ LEVEL │ │
├──────────┼──────────┼───────────┼──────────────────────────────────────────────────────┤
│ IgM │ pentamer │ ~1.5 mg/ │ First antibody made; best complement activator │
│ │ (10 Fab │ mL │ (C1q binding); poor opsonin alone; low affinity │
│ │ arms!) │ │ compensated by avidity; BCR monomer on naive B cells │
├──────────┼──────────┼───────────┼──────────────────────────────────────────────────────┤
│ IgG │ monomer │ ~12 mg/mL │ Most abundant; 4 subclasses (IgG1–4); opsonization; │
│ │ │ (dominant)│ ADCC; complement (IgG1,3); crosses placenta; │
│ │ │ │ FcRn extends half-life to ~21 days │
├──────────┼──────────┼───────────┼──────────────────────────────────────────────────────┤
│ IgA │ dimer │ ~2 mg/mL │ Mucosal immunity; secretory IgA in gut, lung, │
│ │ (secreto-│ │ saliva, breast milk; J-chain + secretory component; │
│ │ ry form)│ │ does NOT activate complement efficiently │
├──────────┼──────────┼───────────┼──────────────────────────────────────────────────────┤
│ IgE │ monomer │ <0.001 │ Bound to mast cells/basophils via FcεRI; │
│ │ │ mg/mL │ antigen cross-linking → degranulation → allergy; │
│ │ │ (trace!) │ evolved for parasites; hijacked in atopy │
├──────────┼──────────┼───────────┼──────────────────────────────────────────────────────┤
│ IgD │ monomer │ trace │ Co-expressed with IgM on naive B cells; │
│ │ │ │ exact effector role still debated │
└──────────┴──────────┴───────────┴──────────────────────────────────────────────────────┘
CLASS SWITCH RECOMBINATION (CSR):
V-D-J ── Cμ → V-D-J ── Cγ1 (IgM → IgG1)
↑ same antigen specificity; different Fc effector function
cytokines instruct the switch: IL-4 → IgE/IgG1; TGF-β → IgA; IFN-γ → IgG2a
This diagram maps the physical domains of an IgG molecule to their functions and then compares all five isotypes by structure, abundance, and effector role, making clear that class switching changes the Fc region while preserving antigen specificity encoded in the V(D)J segments.
---Diagram 3: V(D)J Recombination and the Sources of Antibody Diversity
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ HOW ONE GENOME ENCODES ~10¹¹ DIFFERENT ANTIBODIES: V(D)J RECOMBINATION ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
GERMLINE HEAVY CHAIN LOCUS (chromosome 14, simplified)
────────────────────────────────────────────────────────────────────────────────────────────
┌───┬───┬─ ─ ─┬───┐ ┌───┬─ ─ ─┬───┐ ┌───┬─ ─ ─┬───┐ ┌────┬────┬────┬────┬────┐
│VH1│VH2│ │VH40│ │DH1│ │DH27│ │JH1│ │JH6│ │ Cμ │ Cδ │ Cγ │ Cε │ Cα │
└───┴───┴─ ─ ─┴───┘ └───┴─ ─ ─┴───┘ └───┴─ ─ ─┴───┘ └────┴────┴────┴────┴────┘
~40 functional VH ~27 DH 6 JH constant regions
STEP 1: RAG1/RAG2 recombinase recognizes RECOMBINATION SIGNAL SEQUENCES (RSS)
RSS = heptamer ── 12 or 23 bp spacer ── nonamer
"12/23 rule": V joins D (23+12), D joins J (12+23) — prevents V directly joining J
STEP 2: COMBINATORIAL JOINING
Choose 1 VH × 1 DH × 1 JH → 40 × 27 × 6 = ~6,480 heavy chain combinations
Light chain (κ or λ): choose 1 Vκ × 1 Jκ → ~200 combinations
Heavy × Light pairing: 6,480 × 200 ≈ 1.3 × 10⁶ combinations already
STEP 3: JUNCTIONAL DIVERSITY (the big amplifier — adds ~10⁵× more diversity)
┌─────────────────────────────────────────────────────────────────┐
│ After RAG cuts: │
│ │
│ VH ────────P-nucleotides (palindromic; from hairpin opening) │
│ ↓ │
│ TdT enzyme adds N-nucleotides │
│ (Terminal deoxynucleotidyl Transferase) │
│ RANDOM, template-independent addition │
│ 0–20 nucleotides at each junction │
│ ↓ │
│ DH ─────────────────────────────────────────── JH │
│ │
│ Result: CDR3 (the most variable loop) encodes junction │
│ → majority of antigen contact surface diversity lives here │
└─────────────────────────────────────────────────────────────────┘
STEP 4: SOMATIC HYPERMUTATION (after antigen encounter, in germinal centers)
AID (Activation-Induced Cytidine Deaminase) mutates V-region DNA
Rate: ~10⁻³ per base per division (10⁶× above normal mutation rate!)
Selection: high-affinity mutants capture antigen → survive
low-affinity mutants → apoptosis (Fas pathway)
Result: AFFINITY MATURATION — antibody Kd can improve 100–10,000× over primary response
DIVERSITY SUMMARY
────────────────────────────────────────────────────────────────────────────────────────────
┌──────────────────────────────────────────┬───────────────────────────┐
│ Source │ Contribution │
├──────────────────────────────────────────┼───────────────────────────┤
│ Combinatorial V(D)J joining │ ~10⁶ │
│ Junctional diversity (P + N nucleotides) │ ×10⁵ │
│ Heavy/light chain pairing │ multiplicative │
│ Somatic hypermutation │ post-activation refinement│
├──────────────────────────────────────────┼───────────────────────────┤
│ ESTIMATED TOTAL REPERTOIRE │ > 10¹¹ │
└──────────────────────────────────────────┴───────────────────────────┘
ALLELIC EXCLUSION: once a productive rearrangement occurs,
RAG is shut down → each B cell expresses exactly ONE antibody specificity
This diagram walks through all four layers of antibody diversity generation — germline segment number, combinatorial joining, junctional nucleotide additions by TdT, and post-activation somatic hypermutation — showing how a ~25,000-gene genome can produce a repertoire exceeding 100 billion distinct specificities.
---Diagram 4: T Cell Activation Signal Integration and Downstream Fates
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ T CELL ACTIVATION: THREE SIGNALS, FOUR OUTCOMES ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
ANTIGEN-PRESENTING CELL (dendritic cell)
┌────────────────────────────────────────────────────────────┐
│ │
│ pMHC-II ──── B7-1/B7-2 ──── cytokines │
│ (signal 1) (signal 2) (signal 3) │
│ │
└──────┬──────────────┬───────────────┬─────────────────────┘
│ │ │
↓ ↓ ↓
┌─────────────────┐ ┌──────────────┐ ┌──────────────────────────┐
│ TCR + CD3 + CD4 │ │ CD28 binds │ │ Cytokine receptor │
│ │ │ B7 │ │ on T cell surface │
│ Lck (CD4-assoc) │ │ │ │ │
│ phosphorylates │ │ PI3K → Akt │ │ → drives lineage choice │
│ ITAM motifs │ │ (survival, │ │ │
│ on CD3ζ chain │ │ metabolism) │ │ │
└────────┬────────┘ └──────┬───────┘ └───────────┬──────────────┘
│ │ │
↓ ↓ │
┌─────────────────┐ ┌──────────────┐ │
│ ZAP-70 recruited│ │ NF-κB pathway│ │
│ phosphorylates │ │ activated │ │
│ LAT adaptor │ │ → IL-2 gene │ │
└────────┬────────┘ └──────┬───────┘ │
│ │ │
↓ │ │
┌─────────────────┐ │ │
│ PLCγ1 → DAG │ │ │
│ + IP3 │ │ │
│ │ │ │
│ IP3 → Ca²⁺ release │ │
│ → calcineurin │ │ │
│ → NFAT │ │ │
│ dephosphoryl- │ │ │
│ ation → nucleus│ │ │
└────────┬────────┘ │ │
│ │ │
└──────────┬────────┘ │
↓ │
┌──────────────────────┐ │
│ IL-2 PRODUCTION │ │
│ + IL-2 RECEPTOR │ │
│ UPREGULATION │ │
│ (autocrine loop) │ │
│ → clonal expansion │ │
└──────────┬───────────┘ │
│ │
└────────────┬───────────────────┘
│ SIGNAL 3 (cytokine milieu) determines fate
↓
┌──────────────────────────────────────────────────────┐
│ EFFECTOR T CELL LINEAGES │
├────────────┬────────────┬────────────┬───────────────┤
│ Th1 │ Th2 │ Th17 │ Treg │
│ │ │ │ │
│ Inducing │ Inducing │ Inducing │ Inducing │
│ cytokine: │ cytokine: │ cytokines: │ cytokines: │
│ IL-12, │ IL-4 │ TGF-β + │ TGF-β │
│ IFN-γ │ │ IL-6 │ (+ IL-2) │
│ │ │ │ │
│ TF: T-bet │ TF: GATA-3 │ TF: RORγt │ TF: FoxP3 │
│ │ │ │ │
│ Makes: │ Makes: │ Makes: │ Makes: │
│ IFN-γ │ IL-4,5,13 │ IL-17A, │ IL-10, │
│ │ │ IL-22 │ TGF-β │
│ │ │ │ │
│ Function: │ Function: │ Function: │ Function: │
│ intracell- │ helminth │ barrier │ suppress │
│ ular patho-│ defense; │ defense │ autoreactive │
│ gens; IFN-γ│ allergy! │ fungi, │ T cells; │
│ activates │ │ extracell │ peripheral │
│ macrophages│ │ bacteria │ tolerance │
└────────────┴────────────┴────────────┴───────────────┘
SIGNAL 1 ALONE → anergy (T cell silenced; no IL-2 production)
SIGNAL 1 + 2 → activation + clonal expansion
SIGNAL 1 + 2 + 3 → specific effector fate
CTLA-4 (on T cell) competes with CD28 for B7 → dominant inhibitory signal
PD-1 (on exhausted T cells) + PD-L1 (on tumor/DC) → exhaustion; checkpoint blockade target
This diagram integrates the three-signal model of T cell activation — TCR engagement, CD28 co-stimulation, and cytokine instruction — with the downstream signal transduction cascade (Lck → ZAP-70 → NFAT → IL-2) and the cytokine-determined bifurcation into distinct effector lineages, each with its own master transcription factor.
---Diagram 5: Immunogenicity of Therapeutic Proteins — Risk Cascade and FDA Expectations
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ IMMUNOGENICITY OF PROTEIN THERAPEUTICS: FROM MOLECULE TO CLINICAL CONSEQUENCE ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
RISK FACTORS THAT DRIVE IMMUNOGENICITY
──────────────────────────────────────────────────────────────────────────────────────────
PRODUCT-RELATED PATIENT-RELATED PROCESS-RELATED
┌────────────────────────────┐ ┌───────────────────────┐ ┌──────────────────┐
│ • Non-human sequences │ │ • HLA genotype │ │ • Host cell │
│ (murine CDRs) │ │ (MHC polymorphism │ │ impurities │
│ • Aggregates (worst risk!) │ │ determines T cell │ │ (HCPs, DNA) │
│ • Denatured/misfolded │ │ epitope binding) │ │ • Glycosylation │
│ protein │ │ • Prior exposure │ │ patterns │
│ • Formulation (route, │ │ • Immune status; │ │ • Leachables │
│ adjuvants, excipients) │ │ immunosuppression │ │ from container │
│ • T cell epitope content │ │ • Regulatory T cell │ │ • Aggregation │
│ (predicted by │ │ function │ │ during storage │
│ in silico tools) │ └───────────────────────┘ └──────────────────┘
└────────────────────────────┘
↓ these factors combine to determine:
THE IMMUNOGENICITY CASCADE
──────────────────────────────────────────────────────────────────────────────────────────
THERAPEUTIC PROTEIN
ADMINISTERED
│
│ protein taken up by DC
↓
ANTIGEN PROCESSING
(endolysosomal; MHC II)
│
│ peptide-MHC II presented to CD4+ T cells
↓
T CELL EPITOPE
RECOGNITION
│
├─→ T cell activation → help to B cells
│
↓
B CELL ACTIVATION
+ GERMINAL CENTER REACTION
│
↓
ANTI-DRUG ANTIBODIES (ADAs)
│
├──────────────────────────────────────────────────────────┐
│ │
↓ ↓
BINDING ADAs NEUTRALIZING ADAs
(may not affect efficacy; (block drug binding site;
may increase clearance) directly ablate efficacy;
worst outcome for
endogenous proteins:
e.g., anti-EPO Ab
→ pure red cell aplasia)
IN SILICO T CELL EPITOPE ASSESSMENT (De Groot & Scott 2007)
──────────────────────────────────────────────────────────────────────────────────────────
┌─────────────────────────────────────────────────────────────────────────────────────┐
│ │
│ Protein sequence │
│ ↓ │
│ Sliding-window peptide scanning (typically 9-mer or 15-mer windows) │
│ ↓ │
│ MHC binding prediction across common HLA alleles (HLA-DR supertypes) │
│ ↓ │
│ Promiscuous binders (bind many HLA alleles) = HIGH RISK epitopes │
│ ↓ │
│ Compare to human proteome: if sequence matches self → tolerance; lower risk │
│ If sequence is novel/foreign → no central tolerance → higher risk │
│ ↓ │
│ "Immunogenicity score" guides protein engineering (deimmunization) │
│ │
└─────────────────────────────────────────────────────────────────────────────────────┘
FDA EXPECTATIONS FOR SYNTHETIC PEPTIDE GENERICS (2021 Guidance)
──────────────────────────────────────────────────────────────────────────────────────────
┌─────────────────────────────────────────────────────────────────────────────────────┐
│ When a synthetic peptide ANDA references an rDNA-derived listed drug: │
│ │
│ • Demonstrate STRUCTURAL identity (sequence, disulfide bonds, modifications) │
│ • Characterize impurity profile (synthetic route impurities differ from rDNA) │
│ • Immunogenicity comparison study may be REQUIRED if impurity profile │
│ differs meaningfully from RLD (reference listed drug) │
│ • Aggregation propensity must be assessed (aggregates = potent immunogen) │
│ • Cannot assume same immunogenicity as rDNA originator without data │
└─────────────────────────────────────────────────────────────────────────────────────┘
This diagram maps the full immunogenicity risk cascade for protein therapeutics — from molecular risk factors through antigen processing and T cell help to ADA formation — and connects it to in silico prediction strategies and FDA regulatory expectations for synthetic peptide generics that reference rDNA-derived listed drugs.
---Key Takeaways
- MHC class I presents peptides 8–10 amino acids long derived from the cytosol via the proteasome → TAP1/TAP2 transporter → ER loading sequence, and is expressed on all nucleated cells. MHC class II presents peptides 13–25 amino acids long from the endolysosomal pathway and is restricted to professional antigen-presenting cells (dendritic cells, macrophages, B cells). The distinction is not decorative — it determines which T cell subset responds and therefore whether the response is cytotoxic or helper in character. (Abbas et al., Ch. 6; Janeway's, Ch. 6)
- HLA-DM is the essential catalyst of MHC II peptide loading. Without it, the invariant chain-derived CLIP peptide would occupy the MHC II groove indefinitely, blocking antigen presentation. HLA-DM functions like a nucleotide exchange factor: it destabilizes CLIP and stabilizes the groove until a high-affinity antigenic peptide takes over. This is a beautiful structural parallel to the GEF–GTPase relationship Skipper encountered in signal transduction. (Janeway's, Ch. 6)
- T cell activation requires three distinct signals. Signal 1 (TCR–pMHC) alone induces anergy, not activation. Signal 2 (CD28–B7 co-stimulation) provides survival and metabolic support via PI3K/Akt. Signal 3 (cytokine milieu from the APC and tissue) directs lineage commitment. The master transcription factors are: T-bet (Th1), GATA-3 (Th2), RORγt (Th17), and FoxP3 (Treg). Cytokines that instruct these fates include: IL-12 + IFN-γ → Th1; IL-4 → Th2; TGF-β + IL-6 → Th17; TGF-β alone → Treg. (Abbas et al., Ch. 9–10)
- The TCR signal transduction cascade runs: Lck → ZAP-70 → LAT → PLCγ1 → IP3/DAG. IP3 releases Ca²⁺ from the ER, activating calcineurin, which dephosphorylates NFAT, allowing it to enter the nucleus and drive IL-2 transcription. DAG activates PKC-θ → NF-κB. Cyclosporin A and tacrolimus (FK506) block calcineurin — which is precisely why they suppress T cell-mediated transplant rejection. This is a direct clinical application of the signaling biochemistry Skipper studied in earlier courses. (Abbas et al., Ch. 7)
- V(D)J recombination generates antibody diversity through four compounding mechanisms: (a) combinatorial joining of ~40 VH × 27 DH × 6 JH segments (heavy chain); (b) combinatorial pairing of heavy and light chains; (c) junctional diversity from TdT-mediated N-nucleotide addition and palindromic P-nucleotide insertion at coding joints, which is template-independent and targeted precisely at the CDR3 loop; and (d) allelic exclusion ensuring each B cell expresses a single specificity. The total pre-immune repertoire exceeds 10¹¹. (Janeway's, Ch. 5)
- Somatic hypermutation (SHM) occurs in germinal centers at a rate ~10⁶-fold above the normal genomic mutation rate (~10⁻³ per base per cell division vs. ~10⁻⁹ for the rest of the genome). It is catalyzed by AID (Activation-Induced Cytidine Deaminase), which deaminates cytosines in single-stranded DNA within V-region sequences. Selection within the germinal center — B cells must capture antigen on follicular dendritic cells and receive T follicular helper (Tfh) signals to survive — drives affinity maturation, improving antibody Kd by 100–10,000-fold over the primary response. (Abbas et al., Ch. 12)
- IgM is the first antibody produced and the most potent activator of the classical complement pathway because its pentameric structure (10 antigen-binding arms) allows a single molecule to present multiple Fc regions simultaneously, lowering the threshold for C1q binding. Despite low per-site affinity, its avidity is enormous. IgG dominates secondary responses due to class switching, has a serum half-life of ~21 days (mediated by FcRn recycling), and is the only isotype that crosses the placenta to confer passive neonatal immunity. (Abbas et al., Ch. 5, 13)
- Class switch recombination (CSR) changes antibody effector function without altering antigen specificity. The V(D)J exon is the same; only the constant region downstream of it changes via AID-mediated switch region recombination. The cytokine environment determines which isotype is selected: IL-4 → IgE and IgG1 in mice; TGF-β → IgA; IFN-γ → IgG2a. This is why the cytokine milieu at the time of B cell activation — shaped by the Th subset — determines not just whether antibody is made but what class of antibody and therefore what effector mechanism is deployed. (Janeway's, Ch. 10)
- IgE is present at vanishingly low concentrations in serum (<0.001 mg/mL) but has disproportionate biological impact because it is pre-loaded onto the high-affinity FcεRI receptor on mast cells and basophils. When antigen cross-links these receptor-bound IgE molecules, degranulation releases histamine, prostaglandins, and leukotrienes within seconds. This is the molecular basis of Type I (immediate) hypersensitivity — allergy and anaphylaxis. IgE almost certainly evolved to expel helminths; in populations with low parasite burden, it has been co-opted into atopic disease. (Abbas et al., Ch. 14; Janeway's, Ch. 14)
- The complement system has three activation pathways (classical: C1q binds IgG/IgM–antigen complexes; lectin: MBL binds mannose on pathogens; alternative: spontaneous C3 hydrolysis on unprotected surfaces) that all converge on C3 convertase, generating C3b (opsonin), C3a/C5a (anaphylatoxins that recruit neutrophils and increase vascular permeability), and ultimately the membrane attack complex (MAC: C5b-6-7-8-9), which forms a pore in lipid bilayers. Pathogens evade complement by recruiting host regulators like factor H, a strategy exploited by many bacteria and viruses. (Abbas et al., Ch. 13)
- Central tolerance depends on AIRE (Autoimmune Regulator), a transcription factor expressed in medullary thymic epithelial cells that drives ectopic expression of peripheral tissue antigens (insulin, thyroglobulin, retinal proteins) in the thymus. T cells that react too strongly to these self-peptides on MHC undergo apoptosis (negative selection). Loss-of-function mutations in AIRE cause APS-1 (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy), a multi-organ autoimmune disease that directly demonstrates what happens when this tolerance checkpoint fails. (Janeway's, Ch. 8)
- Aggregated proteins are the most potent drivers of immunogenicity for biologic therapeutics. Aggregates act as T-independent antigens that can cross-link BCRs and trigger B cell activation without T cell help, and they also activate innate immune pathways (TLRs, inflammasome) that provide the danger signals needed for APC maturation. De Groot and Scott (2007) identified T cell epitope content (assessed by in silico MHC-II binding prediction across common HLA supertypes) as the second critical predictor. Deimmunization — mutating or deleting high-risk T cell epitopes — is a rational approach to reducing ADA liability. (De Groot & Scott, 2007)
- The FDA's 2021 guidance for synthetic peptide ANDAs referencing rDNA-derived listed drugs requires head-to-head characterization of impurity profiles because synthetic chemical manufacturing introduces different process-related impurities (truncated sequences, diastereomers, coupling agent residues) than recombinant production (host cell proteins, glycoforms). Because impurities can act as adjuvants or alter aggregation state, FDA may require immunogenicity bridging data — not merely structural equivalence — before approving the generic. This is a regulatory consequence of the mechanistic science covered in this course. (FDA CDER, 2021)
- Monoclonal antibody therapeutics have evolved through four generations of humanization to reduce immunogenicity: murine mAbs (fully murine, ~30% ADA rate), chimeric mAbs (murine V regions + human Fc; ~15% ADA rate, suffix -ximab), humanized mAbs (murine CDRs grafted onto human framework; suffix -zumab), and fully human mAbs (from transgenic mice or phage display; suffix -umab). Each step reduces the foreign sequence content and therefore the T cell epitope burden, directly applying the mechanistic principles of antigen processing and HLA-restricted presentation. (Abbas et al., Ch. 5)
- Thymic positive selection requires that T cells recognize self-MHC with at least weak affinity; negative selection eliminates those that recognize self-MHC + self-peptide with high affinity. This creates an exquisitely narrow window of acceptable TCR affinity — strong enough to see MHC, weak enough not to attack self. The entire specificity of the adaptive immune system for self-MHC (MHC restriction, demonstrated by Zinkernagel and Doherty in 1974 for which they received the 1996 Nobel Prize) is a consequence of this thymic education process, not an intrinsic property of the TCR gene segments. (Janeway's, Ch. 8)
References
- Abbas, Abul K., Lichtman, Andrew H., and Pillai, Shiv. Cellular and Molecular Immunology, 10th edition. Elsevier, Philadelphia, 2021. ISBN 978-0-323-52324-0.
- Murphy, Kenneth, Weaver, Casey, and Berg, Leslie. Janeway's Immunobiology, 10th edition. W.W. Norton & Company, New York, 2022. ISBN 978-0-393-67122-5.
- De Groot, Anne S. and Scott, David W. 'Immunogenicity of protein therapeutics.' Trends in Immunology, vol. 28, no. 11, pp. 482–490, 2007. DOI: 10.1016/j.it.2007.07.011
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 'ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry.' FDA, Silver Spring, MD, 2021. Available at: https://www.fda.gov/media/103864/download
- Zinkernagel, Rolf M. and Doherty, Peter C. 'Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.' Nature, vol. 248, no. 5450, pp. 701–702, 1974. DOI: 10.1038/248701a0 [Seminal paper establishing MHC restriction; conceptual foundation for antigen presentation.]
- Tonegawa, Susumu. 'Somatic generation of antibody diversity.' Nature, vol. 302, no. 5909, pp. 575–581, 1983. DOI: 10.1038/302575a0 [Nobel Prize 1987; foundational paper demonstrating V(D)J recombination.]
- Anderson, Mark S., et al. 'Projection of an immunological self shadow within the thymus by the Aire protein.' Science, vol. 298, no. 5597, pp. 1395–1401, 2002. DOI: 10.1126/science.1075958 [Established the mechanistic role of AIRE in central tolerance.]